believe study of bimagrumab + semaglutide Bimagrumab-Semaglutide Combination Achieves Significant Weight Loss While Preserving Muscle Mass Bimagrumab Dosing Protocols and Administration

Published online April 18, 2025

Developed by Novo Nordisk as a glucagon-like peptide-1 receptor agonist (GLP-1 RA), semaglutide emerged from efforts to create longer-acting diabetes medications with improved glycemic control and potential cardiovascular benefits

You may notice you eat less at meals, feel satisfied sooner, and experience fewer cravings throughout the day

When you know what to expect and when to expect it, the experience shifts from alarming to manageable

Product Specifications Each vial in the Semaglutide Weight Loss Program with B-12 & Glycine is compounded for provider-prescribed use and includes the following formulation details: Per Vial Composition: Semaglutide + B-12 + Glycine Strength: 5 mg / 5 mg / 1 mg per mL Total Vial Size: 2 mL Form: Sterile injectable solution Total Active Content Per Vial: Semaglutide: 10 mg total per vial B-12: 10 mg total per vial Glycine: 2 mg total per vial Ordering Information: Maximum: Up to 3 vials per order Prescription required before fulfillment Compounded by a licensed pharmacy following provider approval All Wellness Medicines and Compounded Pharmacy Products require a Quick & Easy Medical Evaluation to Ensure the Medication is Appropriate for you

Renal function has minimal impact on semaglutide clearance